William Blair Begins Coverage on Enovis (NYSE:ENOV)

William Blair started coverage on shares of Enovis (NYSE:ENOV) in a report issued on Friday, MarketBeat.com reports. The firm set an “outperform” rating on the stock.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Wells Fargo & Company raised shares of Enovis to a “strong-buy” rating in a research note on Wednesday, March 18th. Zacks Research raised shares of Enovis from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 4th. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a research note on Monday, March 30th. Finally, BTIG Research raised their target price on shares of Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $47.43.

Enovis Trading Up 4.5%

Shares of Enovis stock opened at $26.32 on Friday. Enovis has a 12-month low of $21.00 and a 12-month high of $37.85. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -1.27 and a beta of 1.47. The company has a current ratio of 2.02, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85. The company’s 50-day moving average price is $23.39 and its 200-day moving average price is $26.40.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The firm had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. During the same period in the prior year, the firm posted $0.98 earnings per share. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts expect that Enovis will post 2.79 earnings per share for the current fiscal year.

Insider Activity at Enovis

In other Enovis news, insider Oliver Engert purchased 1,000 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were purchased at an average cost of $25.50 per share, with a total value of $25,500.00. Following the completion of the purchase, the insider owned 43,640 shares of the company’s stock, valued at $1,112,820. The trade was a 2.35% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have purchased 5,000 shares of company stock worth $121,983 over the last quarter. Company insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Arax Advisory Partners purchased a new position in shares of Enovis during the fourth quarter worth approximately $29,000. Farther Finance Advisors LLC raised its stake in shares of Enovis by 42.8% during the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after acquiring an additional 367 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares in the last quarter. SJS Investment Consulting Inc. raised its stake in shares of Enovis by 30,340.0% during the third quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock worth $46,000 after acquiring an additional 1,517 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Enovis by 353.5% during the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock worth $49,000 after acquiring an additional 1,446 shares in the last quarter. 98.45% of the stock is owned by hedge funds and other institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.